APA (7th ed.) Citation

D, B., & KR, R. (2016). Letter: Should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir? Authors' reply. Alimentary pharmacology & therapeutics, 43(9), 1022. https://doi.org/10.1111/apt.13586

Chicago Style (17th ed.) Citation

D, Banerjee, and Reddy KR. "Letter: Should HCV Cirrhotics with High Bilirubin or Gilbert's Syndrome Be Excluded from Paritaprevir, Ombitasvir, or Dasabuvir? Authors' Reply." Alimentary Pharmacology & Therapeutics 43, no. 9 (2016): 1022. https://doi.org/10.1111/apt.13586.

MLA (9th ed.) Citation

D, Banerjee, and Reddy KR. "Letter: Should HCV Cirrhotics with High Bilirubin or Gilbert's Syndrome Be Excluded from Paritaprevir, Ombitasvir, or Dasabuvir? Authors' Reply." Alimentary Pharmacology & Therapeutics, vol. 43, no. 9, 2016, p. 1022, https://doi.org/10.1111/apt.13586.